Key points are not available for this paper at this time.
Background: Insulin-like growth factor-1 (IGF-1) plays a role in metabolism and immune regulation. Although obesity is associated with chronic inflammation, the relationship between IGF-1 levels and systemic inflammatory markers remains unclear. This study aimed to examine the association between IGF-1 levels, systemic inflammation, and metabolic comorbidities in individuals with obesity. Methods: This retrospective cross-sectional study included 214 adults with a BMI ≥35 kg/m 2 evaluated between June 2019 and March 2025. Participants were classified as low IGF-1 (standard deviation score SDS ≤ −2.0) or standard IGF-1 (−2.0 < SDS < 2.0). Clinical and laboratory data were analyzed, including neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio, lymphocyte-to-monocyte ratio, systemic immune-inflammation index (SII), systemic inflammation response index, and systemic inflammation aggregate index. Results: Low IGF-1 was identified in 8.88% of patients. No differences were found between groups regarding diabetes, dyslipidemia, or hypertension. NLR (2.21 vs. 1.79; p = 0.005) and SII (614.6 vs. 521.8; p = 0.041) were significantly higher in the standard IGF-1 group. SII was positively correlated with systolic blood pressure, alanine aminotransferase, and insulin. IGF-1 SDS was not correlated with inflammatory markers. Conclusions: Lower IGF-1 levels were not associated with higher systemic inflammation. These findings highlight the heterogeneity of inflammatory responses in obesity and suggest the need for further research.
Baykal et al. (Wed,) studied this question.